- Home
- SLG vs CDTX Comparison
SLG vs CDTX Comparison
Compare SLG & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLG
- CDTX
- Stock Information
- Founded
- SLG 1980
- CDTX 2012
- Country
- SLG United States
- CDTX United States
- Employees
- SLG N/A
- CDTX N/A
- Industry
- SLG Real Estate Investment Trusts
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLG Real Estate
- CDTX Health Care
- Exchange
- SLG Nasdaq
- CDTX Nasdaq
- Market Cap
- SLG 3.4B
- CDTX 2.8B
- IPO Year
- SLG 1997
- CDTX 2015
- Fundamental
- Price
- SLG $43.73
- CDTX $219.50
- Analyst Decision
- SLG Buy
- CDTX Buy
- Analyst Count
- SLG 15
- CDTX 13
- Target Price
- SLG $63.00
- CDTX $119.44
- AVG Volume (30 Days)
- SLG 1.2M
- CDTX 2.2M
- Earning Date
- SLG 10-15-2025
- CDTX 11-06-2025
- Dividend Yield
- SLG 7.19%
- CDTX N/A
- EPS Growth
- SLG N/A
- CDTX N/A
- EPS
- SLG N/A
- CDTX N/A
- Revenue
- SLG $661,814,000.00
- CDTX N/A
- Revenue This Year
- SLG N/A
- CDTX N/A
- Revenue Next Year
- SLG $9.79
- CDTX N/A
- P/E Ratio
- SLG N/A
- CDTX N/A
- Revenue Growth
- SLG N/A
- CDTX N/A
- 52 Week Low
- SLG $42.92
- CDTX $15.22
- 52 Week High
- SLG $80.90
- CDTX $220.41
- Technical
- Relative Strength Index (RSI)
- SLG 26.19
- CDTX 89.20
- Support Level
- SLG $49.20
- CDTX $102.46
- Resistance Level
- SLG $45.34
- CDTX $220.41
- Average True Range (ATR)
- SLG 1.81
- CDTX 3.89
- MACD
- SLG -0.52
- CDTX 11.65
- Stochastic Oscillator
- SLG 8.68
- CDTX 99.19
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.